The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 112.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,500.00
High: 12,586.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 6-Oil slips further on Europe demand concerns

Wed, 17th Mar 2021 05:25

* API report shows surprise drop in U.S. crude inventories

* No policy shift expected by U.S. Federal Reserve

* IEA says demand won't reach pre-pandemic level until 2023

* Coming up: EIA report, 1430 GMT
(Updates prices, adds French COVID-19 measures, WHO on vaccine)

By Alex Lawler

LONDON, March 17 (Reuters) - Oil slipped for a fourth day on
Wednesday as concerns about weaker demand in Europe outweighed
an industry report that showed U.S. crude inventories fell
unexpectedly last week.

Several European countries have paused the use of
AstraZeneca's COVID-19 vaccine on worries over possible side
effects. Germany is seeing rising coronavirus cases, Italy is
imposing a nationwide Easter lockdown and France plans to impose
tougher curbs.

Brent crude was down 38 cents, or 0.6%, at $68.01 a
barrel by 1410 GMT, having pared earlier losses. U.S. West Texas
Intermediate (WTI) crude dropped 35 cents, or 0.5%, to
$64.45.

"The suspension will not do the bloc's economic and fuel
recovery any favours," said Stephen Brennock of oil broker PVM.
"The hope now is that Europe can get its sluggish vaccine
rollout back on track."

A World Health Organization (WHO) vaccine safety panel on
Wednesday said the benefits of the AstraZeneca vaccine
outweigh its risks and recommends that vaccinations continue.

Oil prices were also pressured by the latest reports from
the International Energy Agency, which said a supercycle is
unlikely and demand is not expected to return to pre-pandemic
levels until 2023.

"IEA's report has triggered action among oil traders," said
Naeem Aslam of Avatrade. "We have seen some selling."

Still, oil has recovered from historic lows reached last
year as demand collapsed, buoyed by record oil output cuts by
the Organization of the Petroleum Exporting Countries (OPEC) and
its allies. Brent reached $71.38 on March 8, its highest since
Jan. 8, 2020.

The market gained support, however, from American Petroleum
Institute data, which trading sources said Ushowed U.S. crude
inventories fell by 1 million barrels last week. Analysts had
expected a rise.

Traders will be looking to the official U.S. Energy
Information Administration report at 1430 GMT for confirmation
of the API figures.

Investors are also looking to the results of the U.S.
central bank's Federal Open Market Committee meeting. No policy
shift is expected.

A rising dollar ahead of the Fed's announcement was also a
headwind for oil because a stronger dollar makes crude more
expensive for holders of other currencies.
(Additional reporting by Roslan Khasawneh in Singapore and
Sonali Paul in Melbourne; Editing by Jacqueline Wong and David
Goodman)

More News
Today 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
Today 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.